Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 10/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | YES1 | P07947 | 3/20 | 0.42 |
| ▸ | ABL1 | P00519 | 2/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14901150 | 0.91 | MAPK1 (0.42) | MAPTSMN1; SMN2ALDH1A1GLAGAA | |
| SCHEMBL14901215 | 0.90 | ATR (0.44) | MAPTSMN1; SMN2ALDH1A1GLAGAA | |
| SCHEMBL14901144 | 0.87 | FGFR1 (0.43) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL14901120 | 0.85 | FGFR3 (0.54) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL14901156 | 0.83 | FGFR3 (0.47) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL14901118 | 0.82 | MAPK1 (0.53) | MAPTSMN1; SMN2ALDH1A1GLAGAA | |
| SCHEMBL14901254 | 0.80 | FGFR1 (0.49) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL14901298 | 0.80 | TTK (0.49) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL14901155 | 0.80 | TTK (0.42) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL16125149 | 0.79 | FGFR1 (0.45) | MAPK1FGFR1FGFR2FGFR4FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776435-B1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LTD (GB) | 2018-06-27 | — | — | EP | disclosed |
| US-10004733-B2 | — | — | 2018-06-26 | — | — | US | disclosed |
| US-20160235744-A1 | SUBSTITUTED PYRIDO[2,3-b]PYRAZINES AS FGFR KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-08-18 | — | — | US | disclosed |
| US-9309242-B2 | Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2016-04-12 | — | — | US | disclosed |
| US-20140288053-A1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2014-09-25 | — | — | US | disclosed |
| WO-2013061080-A1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10004733-B2 | — | SDHB, SDHA, NDUFS5 | MAPT 1643/4885SMN1; SMN2 1885/4885ALDH1A1 205/4885 |
| US-20140288053-A1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | FGFR1, FGFR2, FGFR4 | MAPT 1657/4885SMN1; SMN2 3071/4885ALDH1A1 1576/4885 |
| US-20160235744-A1 | SUBSTITUTED PYRIDO[2,3-b]PYRAZINES AS FGFR KINASE INHIBITORS | FGFR1, FGFR2, FGFR3 | MAPT 1590/4885SMN1; SMN2 3120/4885ALDH1A1 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.